← Back to Home

How Can Recurrence Be Reduced After Liver Cancer Resection? Personalized DNA Vaccine Enters Phase 2 Randomized Trial

Geneos is advancing a personalized cancer vaccine into postsurgical treatment, with plans to enroll 90 patients at high risk of recurrence and compare it with regular monitoring. The new trial will test whether an immunotherapy made using tumor mutations can offer protection when cancer is no longer visible on imaging.

By SURL BioNews

After liver cancer resection, patients may still face recurrence even when no tumor is visible on imaging. How to intervene during this period before visible lesions appear is an important question in postsurgical treatment. On October 21, Geneos Therapeutics announced the launch of IMPACT31, a Phase 2 randomized clinical trial that will use a DNA vaccine made from information about each patient's own tumor to test whether personalized immunotherapy can reduce the risk of recurrence in patients with high-risk hepatocellular carcinoma.

The study, registered as NCT07722741, plans to enroll 90 participants. It uses a multicenter, open-label design and will randomly assign patients who have undergone curative resection to investigational treatment or active surveillance. The company plans to establish trial sites in the United States and the Asia-Pacific region. Active surveillance involves assessing patients' condition through follow-up, rather than discontinuing medical care.

Eligibility for the study is clearly defined. According to registration information from the U.S. National Cancer Institute, participants must have a high risk of recurrence after surgery, show no evidence of disease on magnetic resonance imaging approximately 28 days after surgery, and have tumor tissue available for vaccine development. The trial therefore addresses adjuvant treatment after surgery; it cannot be directly extended to provide evidence of efficacy in patients with existing residual, recurrent, or metastatic lesions.

Production of GNOS-PV02 begins with tumor sequencing: the research team identifies neoantigens arising from mutations in a patient's cancer cells, then encodes the relevant information into DNA plasmids, with the aim of guiding T cells to recognize cancer cells bearing these features. This is a therapeutic vaccine designed to target an existing cancer, and its effectiveness still requires confirmation in clinical trials.

The treatment components also warrant closer examination. The company's announcement refers to the investigational therapy broadly as GNOS-PV02, but the National Cancer Institute information further specifies that the experimental arm includes a personalized neoantigen DNA vaccine and INO-9012, a plasmid encoding interleukin-12. In other words, this comparison evaluates a treatment regimen that includes an immune-stimulating component.

Earlier signals supporting development came from a Phase 1/2 study in advanced hepatocellular carcinoma, in which the vaccine was combined with the immune checkpoint inhibitor pembrolizumab. BioPharm International noted that the study was small and used a single-arm design, making it difficult to distinguish the vaccine's own contribution to efficacy. Results in patients with advanced disease also cannot be directly extrapolated to the prevention of recurrence after surgery.

IMPACT31 thus takes two steps forward: moving the intervention to the postsurgical setting and adding a randomized control group, allowing researchers to compare treatment and surveillance more directly. What has been announced so far is the trial's launch; no efficacy or safety results from this study are yet available. The key questions ahead are whether immune responses can translate into fewer recurrences and whether patients with no visible lesions can gain sufficient practical benefit from undergoing treatment to support its use.

References

  1. The Malaysian Reserve
  2. Geneos Therapeutics
  3. National Cancer Institute
  4. BioPharm International